Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

Diabetes, Obesity and Metabolism

Volumn 15, Issue 4, 2013, Pages 316-323

  Macha, S ^a   Rose, P ^b   Mattheus, M ^b   Pinnetti, S ^b   Woerle, H J ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

BI 10773; Diabetes; Drug drug interaction; Empagliflozin; SGLT2 inhibitor; Warfarin

Indexed keywords

EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; WARFARIN;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84874326639     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12028     Document Type: Article

References (24)

1. World Health Organization Fact Sheet 312. Diabetes. Available from URL: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed 21 September 2011.
2. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
3. Elley CR, Kenealy T, Robinson E, Drury PL. Glycated haemoglobin and cardiovascular outcomes in people with type 2 diabetes: a large prospective cohort study. Diabet Med 2008; 25: 1295-1301.
4. Sarwar N, Gao P, Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
5. Huxley RR, Alonso A, Lopez FL et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the atherosclerosis risk in communities study. Heart 2012; 98: 133-138.
6. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia 1995; 38: 1061-1068.
7. Megherbi SE, Milan C, Minier D, European BIOMED Study of Stroke Care Group et al. Association between diabetes and stroke subtype on survival and functional outcome 3months after stroke: data from the European BIOMED Stroke Project. Stroke 2003; 34: 688-694.
8. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006; 368: 1651-1659.
9. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int 2011; 120: S1-S6.
10. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemic of diabetes mellitus: therapeutic implications. Diabet Med 2010; 27: 136-142.
11. Grempler R, Thomas L, Eckhardt M et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterization and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90.
12. Seman L, Macha S, Nehmiz G, Simons G, Ren B, Pinnetti S, et al. Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clinical Pharmacology in Drug Development 2012 (submitted).
13. Heise T, Seewaldt-Becker E, Macha S et al. BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), is safe and efficacious following 4-week treatment in patients with type 2 diabetes. Diabetes 2010; 59: A172.
14. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 160S-198S.
15. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 546S-592S.
16. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42.
17. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
18. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224.
19. Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: more than just another oral glucose-lowering agent? Expert Opin Investig Drugs 2010; 19: 1581-1589.
20. Schwartz S, Morrow L, Hompesch M et al. Canagliflozin improves glycemic control in subjects with type 2 diabetes (T2D) not optimally controlled on stable doses of insulin. Diabetes 2010; 59: 564P.
21. Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol 2011; 2011: 742719.
22. Hess K, Grant PJ. Inflammation and thrombosis in diabetes. Thromb Haemost 2011; 105: S43-S54.
23. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69: 546-554.
24. Becker RC, Meade TW, Berger PB et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 776S-814S.